> top > docs > PubMed:32673060 > annotations

PubMed:32673060 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T1 932-937 Body_part denotes scale http://purl.obolibrary.org/obo/UBERON_0002542

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T1 56-64 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T2 141-165 Disease denotes coronavirus disease 2019 http://purl.obolibrary.org/obo/MONDO_0100096
T3 167-175 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T4 244-252 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T5 594-602 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T6 615-623 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T7 1154-1163 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T8 1169-1216 Disease denotes severe acute respiratory syndrome coronavirus 2 http://purl.obolibrary.org/obo/MONDO_0100096
T9 1169-1202 Disease denotes severe acute respiratory syndrome http://purl.obolibrary.org/obo/MONDO_0005091
T10 1218-1226 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T11 1305-1314 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T12 1960-1968 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T13 2152-2160 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T14 2322-2330 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T1 66-67 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T2 178-187 http://purl.obolibrary.org/obo/BFO_0000030 denotes OBJECTIVE
T3 358-360 http://purl.obolibrary.org/obo/CLO_0050507 denotes 22
T4 882-886 http://purl.obolibrary.org/obo/CLO_0001000 denotes 3, 5
T5 905-909 http://purl.obolibrary.org/obo/CLO_0001550 denotes a 10
T6 1026-1029 http://purl.obolibrary.org/obo/CLO_0054064 denotes 491
T7 1060-1061 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T8 1270-1271 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T9 1863-1865 http://purl.obolibrary.org/obo/CLO_0050507 denotes 22
T10 2163-2170 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T11 2194-2201 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T1 212-230 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T2 698-716 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T3 1062-1067 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T4 1449-1467 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T5 1656-1674 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T6 1837-1855 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T7 2016-2034 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
2 0-18 Chemical denotes Hydroxychloroquine MESH:D006886
3 56-64 Disease denotes COVID-19 MESH:C000657245
30 141-165 Disease denotes coronavirus disease 2019 MESH:C000657245
31 167-175 Disease denotes COVID-19 MESH:C000657245
32 212-230 Chemical denotes hydroxychloroquine MESH:D006886
33 244-252 Disease denotes COVID-19 MESH:C000657245
34 518-530 Species denotes PARTICIPANTS Tax:9606
35 594-602 Disease denotes COVID-19 MESH:C000657245
36 615-623 Disease denotes COVID-19 MESH:C000657245
37 698-716 Chemical denotes hydroxychloroquine MESH:D006886
38 1030-1038 Species denotes patients Tax:9606
39 1154-1163 Disease denotes infection MESH:D007239
40 1169-1216 Species denotes severe acute respiratory syndrome coronavirus 2 Tax:2697049
41 1218-1228 Species denotes SARS-CoV-2 Tax:2697049
42 1305-1314 Disease denotes infection MESH:D007239
43 1449-1467 Chemical denotes hydroxychloroquine MESH:D006886
44 1633-1645 Species denotes participants Tax:9606
45 1656-1674 Chemical denotes hydroxychloroquine MESH:D006886
46 1814-1826 Species denotes participants Tax:9606
47 1837-1855 Chemical denotes hydroxychloroquine MESH:D006886
48 1960-1968 Disease denotes COVID-19 MESH:C000657245
49 2004-2009 Disease denotes death MESH:D003643
50 2016-2034 Chemical denotes hydroxychloroquine MESH:D006886
51 2087-2092 Disease denotes death MESH:D003643
52 2130-2142 Species denotes participants Tax:9606
53 2152-2162 Species denotes SARS-CoV-2 Tax:2697049
54 2225-2243 Chemical denotes Hydroxychloroquine MESH:D006886
55 2322-2330 Disease denotes COVID-19 MESH:C000657245

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T1 0-65 Sentence denotes Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19:
T2 66-85 Sentence denotes A Randomized Trial.
T3 86-97 Sentence denotes BACKGROUND:
T4 98-177 Sentence denotes No effective oral therapy exists for early coronavirus disease 2019 (COVID-19).
T5 178-188 Sentence denotes OBJECTIVE:
T6 189-283 Sentence denotes To investigate whether hydroxychloroquine could reduce COVID-19 severity in adult outpatients.
T7 284-291 Sentence denotes DESIGN:
T8 292-422 Sentence denotes Randomized, double-blind, placebo-controlled trial conducted from 22 March through 20 May 2020. (ClinicalTrials.gov: NCT04308668).
T9 423-431 Sentence denotes SETTING:
T10 432-517 Sentence denotes Internet-based trial across the United States and Canada (40 states and 3 provinces).
T11 518-531 Sentence denotes PARTICIPANTS:
T12 532-678 Sentence denotes Symptomatic, nonhospitalized adults with laboratory-confirmed COVID-19 or probable COVID-19 and high-risk exposure within 4 days of symptom onset.
T13 679-692 Sentence denotes INTERVENTION:
T14 693-820 Sentence denotes Oral hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 more days) or masked placebo.
T15 821-830 Sentence denotes Measures:
T16 831-938 Sentence denotes Symptoms and severity at baseline and then at days 3, 5, 10, and 14 using a 10-point visual analogue scale.
T17 939-1013 Sentence denotes The primary end point was change in overall symptom severity over 14 days.
T18 1014-1022 Sentence denotes RESULTS:
T19 1023-1108 Sentence denotes Of 491 patients randomly assigned to a group, 423 contributed primary end point data.
T20 1109-1381 Sentence denotes Of these, 341 (81%) had laboratory-confirmed infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or epidemiologically linked exposure to a person with laboratory-confirmed infection; 56% (236 of 423) were enrolled within 1 day of symptoms starting.
T21 1382-1601 Sentence denotes Change in symptom severity over 14 days did not differ between the hydroxychloroquine and placebo groups (difference in symptom severity: relative, 12%; absolute, -0.27 points [95% CI, -0.61 to 0.07 points]; P = 0.117).
T22 1602-1755 Sentence denotes At 14 days, 24% (49 of 201) of participants receiving hydroxychloroquine had ongoing symptoms compared with 30% (59 of 194) receiving placebo (P = 0.21).
T23 1756-1909 Sentence denotes Medication adverse effects occurred in 43% (92 of 212) of participants receiving hydroxychloroquine versus 22% (46 of 211) receiving placebo (P < 0.001).
T24 1910-2010 Sentence denotes With placebo, 10 hospitalizations occurred (2 non-COVID-19-related), including 1 hospitalized death.
T25 2011-2104 Sentence denotes With hydroxychloroquine, 4 hospitalizations occurred plus 1 nonhospitalized death (P = 0.29).
T26 2105-2117 Sentence denotes LIMITATIONS:
T27 2118-2212 Sentence denotes Only 58% of participants received SARS-CoV-2 testing because of severe U.S. testing shortages.
T28 2213-2224 Sentence denotes CONCLUSION:
T29 2225-2331 Sentence denotes Hydroxychloroquine did not substantially reduce symptom severity in outpatients with early, mild COVID-19.
T30 2332-2355 Sentence denotes PRIMARY FUNDING SOURCE:
T31 2356-2371 Sentence denotes Private donors.

maxiaofeng52_800_3

Id Subject Object Predicate Lexical cue
T1 0-18 CI denotes Hydroxychloroquine
T2 212-230 CI denotes hydroxychloroquine
T3 698-716 CI denotes hydroxychloroquine
T4 1449-1467 CI denotes hydroxychloroquine
T5 1656-1674 CI denotes hydroxychloroquine
T6 1837-1855 CI denotes hydroxychloroquine
T7 2016-2034 CI denotes hydroxychloroquine
T8 2225-2243 CI denotes Hydroxychloroquine
T9 812-819 CI denotes placebo
T10 1736-1743 CI denotes placebo
T11 1472-1479 CI denotes placebo
T12 1889-1896 CI denotes placebo
T13 1915-1922 CI denotes placebo
T14 318-325 CI denotes placebo
T15 56-64 DP denotes COVID-19
T16 167-175 DP denotes COVID-19
T17 141-165 DP denotes coronavirus disease 2019
T18 244-252 DP denotes COVID-19
T19 594-602 DP denotes COVID-19
T20 615-623 DP denotes COVID-19
T21 1960-1968 DP denotes COVID-19
T22 2322-2330 DP denotes COVID-19

wangzhuo19_800_3

Id Subject Object Predicate Lexical cue
T1 0-18 CI denotes Hydroxychloroquine
T10 2016-2034 CI denotes hydroxychloroquine
T11 212-230 CI denotes hydroxychloroquine
T12 698-716 CI denotes hydroxychloroquine
T13 1449-1467 CI denotes hydroxychloroquine
T14 1656-1674 CI denotes hydroxychloroquine
T15 1837-1855 CI denotes hydroxychloroquine
T2 2225-2243 CI denotes Hydroxychloroquine
T3 56-64 DP denotes COVID-19
T4 167-175 DP denotes COVID-19
T5 244-252 DP denotes COVID-19
T6 594-602 DP denotes COVID-19
T7 615-623 DP denotes COVID-19
T8 1960-1968 DP denotes COVID-19
T9 2322-2330 DP denotes COVID-19
T16 141-165 DP denotes coronavirus disease 2019
T17 318-325 CI denotes placebo
T18 812-819 CI denotes placebo
T19 1472-1479 CI denotes placebo
T20 1736-1743 CI denotes placebo
T21 1889-1896 CI denotes placebo
T22 1915-1922 CI denotes placebo